Tibet Duo Rui Pharmaceutical Co., Ltd. Class A

Tibet Duo Rui Pharmaceutical Co., Ltd. Class A

SSZSE:301075
42.02
CNY
-1.01
(-2.35%)
-0.26EPS
5.05BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Tibet Duo Rui Pharmaceutical Co., Ltd. Class A carries a market capitalization of 5.05B, placing it among publicly traded companies globally. Its enterprise value stands at 5.00B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap5.05B
Enterprise Value5.00B

Share Statistics

As of September 30, 2026, Tibet Duo Rui Pharmaceutical Co., Ltd. Class A has 80.00M shares outstanding.

Shares Outstanding80.00M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 30.08, and the price-to-book ratio stands at 7.70.

PS Ratio30.08
PB Ratio7.70
P/TBV Ratio8.75

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 30.06 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 5.00B versus a market cap of 5.05B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales30.06

Financial Position

As of September 30, 2026, Tibet Duo Rui Pharmaceutical Co., Ltd. Class A maintains a current ratio of 0.82, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 29.86, indicating elevated leverage, while an interest coverage ratio of -1.69 demonstrates limited ability to service its debt obligations.

Current Ratio0.82
Quick Ratio0.47
Debt / Equity29.86
Debt / EBITDA-11.09
Interest Coverage-1.69

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Tibet Duo Rui Pharmaceutical Co., Ltd. Class A posted a negative return on equity (ROE) of -2.15, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -0.95, reflecting losses generated across the asset base. The company generates approximately 360,496.31 in revenue per employee across its workforce of 461.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.78 indicates how many times Tibet Duo Rui Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-2.15
Return on Assets (ROA)-0.95
Revenue Per Employee360,496.31
Employee Count461.00
Inventory Turnover1.78

Taxes

CNY

Over the twelve months ended September 30, 2026, Tibet Duo Rui Pharmaceutical Co., Ltd. Class A recorded 2.57M in income tax expense. The company reported a pretax loss of -18.34M and -13.88M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax2.57M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Tibet Duo Rui Pharmaceutical Co., Ltd. Class A's stock has declined approximately 20.30% over the past 52 weeks. The 50-day moving average sits at 55.48, while the 200-day moving average is 64.58.

52-Week Price Change-20.30%
50-Day Moving Average55.48
200-Day Moving Average64.58

Income Statement

CNY

Over the twelve months ended September 30, 2026, Tibet Duo Rui Pharmaceutical Co., Ltd. Class A generated 166.19M in revenue and converted that into -13.88M in net income, yielding earnings per share of -0.26. EBITDA reached -18.71M, while operating income came in at -45.08M.

Revenue166.19M
Gross Profit25.80M
Operating Income-45.08M
Pretax Income-18.34M
Net Income-13.88M
EBITDA-18.71M
EBIT-18.71M
Earnings Per Share (EPS)-0.26

Balance Sheet

CNY

As of September 30, 2026, Tibet Duo Rui Pharmaceutical Co., Ltd. Class A holds 302.88M in cash and equivalents against 207.40M in total debt, resulting in a net debt position of -118.26M. Total book value stands at 656.60M, with working capital of -118.92M providing operational flexibility.

Cash & Cash Equivalents302.88M
Total Debt207.40M
Net Debt-118.26M
Equity (Book Value)656.60M
Book Value Per Share8.21
Working Capital-118.92M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-128.59M

Margins

Over the twelve months ended September 30, 2026, Tibet Duo Rui Pharmaceutical Co., Ltd. Class A posted a gross margin of 15.53, reflecting its pricing power and cost economics. The operating margin of -27.12 and net profit margin of -8.35 provide insight into operational efficiency.

Gross Margin15.53
Operating Margin-27.12
Pretax Margin-11.03
Profit Margin-8.35
EBITDA Margin-11.26

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Tibet Duo Rui Pharmaceutical Co., Ltd. Class A paid dividends of 0.07 per share. The dividend payout ratio of -19.17 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.33, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Tibet Duo Rui Pharmaceutical Co., Ltd. Class A shareholders.

Dividend Per Share0.07
Payout Ratio-19.17
Shareholder Yield0.33

Scores

As of September 30, 2026, Tibet Duo Rui Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 3.86, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.86